Form 4: Xencor CEO Dahiyat Reports Equity Grants, Tax-Related Stock Sale

Xencor Inc.'s President and CEO, Bassil I. Dahiyat, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Summary

• Bassil I. Dahiyat, President & CEO and Director of Xencor Inc., reported changes in his beneficial ownership.
• On March 2, 2026, Dahiyat acquired 97,291 shares of common stock in the form of restricted stock units (RSUs) at a price of $0. These RSUs vest in three equal annual installments over three years.
• On March 2, 2026, Dahiyat also acquired 583,748 stock options with an exercise price of $12.3. These options vest 25% after one year and then monthly over the next three years, fully vesting on the four-year anniversary of the grant date.
• On March 3, 2026, Dahiyat disposed of 6,758 shares of common stock at a price of $11.8951 per share. This sale was conducted to satisfy tax withholding obligations upon the vesting of 17,507 restricted stock units.
• Following these transactions, Dahiyat directly owns 567,792 shares of common stock and 583,748 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the significant equity grants align the CEO's long-term interests with shareholders, while the share sale is a routine tax-related event.

Positives

• Grant of 97,291 restricted stock units (RSUs) to the CEO, aligning management's interests with long-term shareholder value.
• Grant of 583,748 stock options to the CEO, providing an incentive for future performance and stock price appreciation.

Negatives

• Sale of 6,758 shares of common stock by the CEO, although this was for tax withholding purposes and not a discretionary sale.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, as it is an insider transaction report. However, the vesting schedules for the RSUs and options extend several years into the future, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that the grant of significant equity awards, including restricted stock units and stock options, to a President & CEO is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to align executive incentives with long-term shareholder value creation, particularly in sectors where product development cycles are lengthy and require sustained leadership. The tax-related sale of shares is a routine event associated with RSU vesting and does not typically signal a change in management's confidence in the company's prospects.

Comparison to Industry Standards

• The equity compensation package for Xencor's CEO, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices in the biotech sector.
• Similar long-term incentive grants are observed at comparable biopharmaceutical companies like Amgen or Regeneron, where executive compensation often heavily features equity to incentivize innovation and successful drug development.
• The specific vesting terms (e.g., 1/3 annually for RSUs, 25% after one year then monthly for options) are standard mechanisms to ensure executive retention and performance alignment over several years.

Stakeholder Impact

• Shareholders: The grant of equity awards to the CEO aligns management's incentives with shareholder value creation over the long term. The tax-related sale is a minor, routine event.
• Employees: No direct impact on general employees is indicated.
• Management: The CEO receives significant long-term equity incentives.

Next Steps

• The restricted stock units will vest in three equal annual installments on the first, second, and third anniversaries of the grant date (March 2, 2026).
• The stock options will vest 25% on the one-year anniversary of March 2, 2026, and 1/48th monthly thereafter, fully vesting on the four-year anniversary.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and a tax-related stock sale, which are standard events and do not provide new fundamental information to warrant a change in investment recommendation. The grants align management incentives with long-term performance, which is generally positive, but the filing itself is not a catalyst for significant price movement.

Keywords

Xencor Inc., XNCR, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Beneficial Ownership, Biotechnology, Pharmaceutical